Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant IBI110 and Sintilimab with Chemotherapy in Resectable Locally Advanced HNSCC
NCT06494943Phase 2Recruiting
- Sponsor
- Fudan University
- Start
- Jun 2024
- Primary completion
- Dec 2026
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label trial of ibi110 in head and neck squamous cell carcinoma (HNSCC) (2 cohorts), sponsored by Fudan University. Primary endpoints: Major Pathological Response and Adverse Events up to 4 months. Started Jun 2024; status: recruiting.
02
Drugs
ibi110
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NCT06494943.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06494943.